sorafenib has been researched along with LSM-2536 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (LSM-2536) | Trials (LSM-2536) | Recent Studies (post-2010) (LSM-2536) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 5 | 0 | 5 |
| Protein | Taxonomy | sorafenib (IC50) | LSM-2536 (IC50) |
|---|---|---|---|
| kappa-type opioid receptor isoform 1 | Homo sapiens (human) | 0.0815 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.081 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y | 1 |
1 review(s) available for sorafenib and LSM-2536
| Article | Year |
|---|---|
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators | 2022 |